SCHEMBL6205912

SCHEMBL6205912

CN(C)C(CCN)Cc1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
OPRK1 P41145 7/20 0.47
SLC6A2 P23975 3/20 0.47
SLC6A4 P31645 2/20 0.47
SLC6A3 Q01959 2/20 0.47
ADRA2B P18089 1/20 0.47
ADRA2C P18825 1/20 0.47
HTR2A P28223 1/20 0.47
ADRA1A P35348 1/20 0.47
KCNH2 Q12809 1/20 0.47
SIGMAR1 Q99720 3/20 0.45
TAAR1 Q96RJ0 2/20 0.45
MAOA P21397 1/20 0.45
CYP2A6 P11509 1/20 0.45
ADORA2A P29274 1/20 0.45
ADORA1 P30542 1/20 0.45
ALDH1A1 P00352 1/20 0.45
CARM1 Q86X55 1/20 0.44
PRMT6 Q96LA8 1/20 0.44
PRMT8 Q9NR22 1/20 0.44
EPHX1 P07099 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL42419 0.84 OPRK1 (0.50) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
SCHEMBL4676268 0.84 OPRK1 (0.50) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
SCHEMBL11117786 0.82 OPRK1 (0.48) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Hydrochloric Acid SCHEMBL29408473 0.82 SLC6A2 (0.48) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Hydrochloric Acid SCHEMBL29408495 0.82 SLC6A2 (0.48) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Hydrochloric Acid SCHEMBL27557899 0.82 SLC6A2 (0.48) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Hydrochloric Acid SCHEMBL5092786 0.81 OPRK1 (0.47) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Iodide SCHEMBL5092821 0.81 OPRK1 (0.47) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
Bromide SCHEMBL5092308 0.81 OPRK1 (0.47) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B
SCHEMBL28131459 0.79 OPRK1 (0.46) OPRK1SLC6A2SLC6A4SLC6A3ADRA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250280696-A1 FORMULATIONS AND USES THEREOF IN OPTOELECTRONIC FIELD Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) 2025-09-04 US disclosed
US-20250275471-A1 BENZOPHENANTHRENE-CONTAINING ORGANIC COMPOUNDS AND USES THEREOF IN ORGANIC OPTOELECTRONIC DEVICES Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) 2025-08-28 US disclosed
US-20250270445-A1 COMPOUNDS AND USES THEREOF IN FIELD OF OPTOELECTRONICS Zhejiang Brilliant Optoelectronic Technology Co.,Ltd. (CN) 2025-08-28 US disclosed
CN-118056803-A Perylene fused phenanthrene organic compound and application thereof in organic electronic device 浙江光昊光电科技有限公司 2024-05-21 CN disclosed
WO-2022213997-A1 COMPOUND AND APPLICATION THEREOF IN PHOTOELECTRIC FIELD 浙江光昊光电科技有限公司 2022-10-13 WO disclosed
WO-2022213993-A1 COMPOSITION AND APPLICATION THEREOF IN PHOTOELECTRIC FIELD 浙江光昊光电科技有限公司 2022-10-13 WO disclosed
WO-2022213996-A1 COMPOUND AND APPLICATION THEREOF IN FIELD OF OPTOELECTRONICS 浙江光昊光电科技有限公司 2022-10-13 WO disclosed
WO-2022214031-A1 MIXTURE AND USE THEREOF IN PHOTOELECTRIC FIELD 浙江光昊光电科技有限公司 2022-10-13 WO disclosed
WO-2022078432-A1 COMPOSITIONS AND USE THEREOF IN PHOTOELECTRIC FIELD 浙江光昊光电科技有限公司 2022-04-21 WO disclosed
WO-2022078456-A1 HIGH POLYMER, COMPOSITION AND ORGANIC PHOTOELECTRIC DEVICE CONTAINING SAME, AND USE THEREOF 浙江光昊光电科技有限公司 2022-04-21 WO disclosed
WO-2022078431-A1 ORGANIC COMPOUND AND USE THEREOF IN PHOTOELECTRIC FIELD 浙江光昊光电科技有限公司 2022-04-21 WO disclosed
EP-3071577-A1 THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS Bayer Pharma Aktiengesellschaft (DE) 2016-09-28 EP disclosed
WO-2015074986-A1 THIENOPYRIMIDINES AS MKNK1 AND MKNK2 INHIBITORS BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2015-05-28 WO disclosed
EP-1505968-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2005-02-16 EP disclosed
WO-2003097047-A1 MULTICYCLIC COMPOUNDS FOR USE AS MELANIN CONCENTRATING HORMONE ANTAGONISTS IN THE TREATMENT OF OBESITY AND DIABETES ELI LILLY AND COMPANY (US) 2003-11-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250280696-A1 FORMULATIONS AND USES THEREOF IN OPTOELECTRONIC FIELD CYP2C19, CYP2C9, ALDH1A2 OPRK1 316/4885SLC6A2 466/4885SLC6A4 542/4885
US-20250270445-A1 COMPOUNDS AND USES THEREOF IN FIELD OF OPTOELECTRONICS CRY1, ALDH1A2, CYBA OPRK1 133/4885SLC6A2 1824/4885SLC6A4 1512/4885
US-20250275471-A1 BENZOPHENANTHRENE-CONTAINING ORGANIC COMPOUNDS AND USES THEREOF IN ORGANIC OPTOELECTRONIC DEVICES TYR, DDT, CYP2C9 OPRK1 77/4885SLC6A2 1090/4885SLC6A4 2575/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.